Skip to main content
SpringerLink
Log in

The Somatopause

An Indication for Growth Hormone Therapy?

  • Current Opinion
  • Published:
Treatments in Endocrinology

Abstract

Human aging causes adverse changes in body composition, a fall in bone mineral density, a deterioration in physical performance, a worsening cardiovascular risk profile, and increased morbidity and mortality. In addition, growth hormone (GH) secretion and serum insulin-like growth factor (IGF)-I levels fall. GH deficiency in adults causes similar changes to those observed with aging, which has led to the suggestion that the elderly are GH deficient and would benefit from GH treatment. Randomized controlled studies have demonstrated modest benefits when GH treatment has been used alone or in combination with exercise or sex steroids. GH treatment in adults over 60 years of age is associated with a high incidence of adverse effects, particularly peripheral edema, arthralgia, and carpal tunnel syndrome. Studies to date have been for a maximum of 12 months, so long-term safety data are not available in this setting. There are particular concerns over the links between the GH-IGF-I axis and the development of cancer in the normal population. Long-term studies are required to determine the efficacy and safety of GH treatment in older adults who are not GH deficient. At the present time, there are insufficient data on sustained efficacy, safety, or cost effectiveness to support the use of GH as an anabolic agent in adults over 60 years of age.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III

Similar content being viewed by others

References

  1. Beck JC, McGarry EE, Dyrenfurth I, et al. Metabolic effects of human and monkey growth hormone in man. Science 1957; 125: 884–5

    Article  PubMed  CAS  Google Scholar 

  2. Raben MS. Treatment of a pituitary dwarf with human growth hormone. J Clin Endocrinol Metab 1958; 18: 901–3

    Article  PubMed  CAS  Google Scholar 

  3. Raben MS. Growth hormone (concluded): 2. Clinical use of human growth hormone. N Engl J Med 1962; 266: 82–6

    Article  PubMed  CAS  Google Scholar 

  4. Rudman D, Kutner MH, Rogers CM, et al. Impaired growth hormone secretion in the adult population: relation to age and adiposity. J Clin Invest 1981; 67: 1361–9

    Article  PubMed  CAS  Google Scholar 

  5. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1–6

    Article  PubMed  CAS  Google Scholar 

  6. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998; 19: 717–97

    Article  PubMed  CAS  Google Scholar 

  7. Carlson HE, Gillin JC, Gorden P, et al. Absence of sleep related growth hormone peaks in aged normal subjects and in acromegaly. J Clin Endocrinol Metab 1972; 34: 1102–5

    Article  PubMed  CAS  Google Scholar 

  8. Iranmanesh A, Lizarralde G, Veldhuis JD. Age and relative obesity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men. J Clin Endocrinol Metab 1991; 73: 1081–8

    Article  PubMed  CAS  Google Scholar 

  9. Ho KY, Evans WS, Blizzard RM, et al. Effects of sex and age on the 24-hour profile of growth hormone secretion in man: importance of endogenous estradiol concentrations. J Clin Endocrinol Metab 1987; 64: 51–8

    Article  PubMed  CAS  Google Scholar 

  10. Weltman A, Weltman JY, Hartman ML, et al. Relationship between age, percentage body fat, fitness and 24-hour growth hormone release in healthy young adults: effect of gender. J Clin Endocrinol Metab 1994; 78: 543–8

    Article  PubMed  CAS  Google Scholar 

  11. Valetto MR, Bellone J, Baffoni C, et al. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Eur J Endocrinol 1996; 135: 568–72

    Article  PubMed  CAS  Google Scholar 

  12. Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet 2000; 356: 1137–42

    Article  PubMed  CAS  Google Scholar 

  13. Muller EE, Cella SG, De-Gennaro-Colonna V, et al. Aspects of the neuroendocrine control of growth hormone secretion in ageing mammals. J Reprod Fertill Suppl 1993; 46: 99–114

    CAS  Google Scholar 

  14. Veldhuis JD, Iranmanesh A, Ho KKY, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab 1991; 72: 51–9

    Article  PubMed  CAS  Google Scholar 

  15. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19: 653–63

    Article  PubMed  CAS  Google Scholar 

  16. Taaffe DR, Pruitt L, Reim J, et al. Effect of recombinant human growth hormone on the muscle strength response to resistance exercise in elderly men. J Clin Endocrinol Metab 1994; 79: 1361–6

    Article  PubMed  CAS  Google Scholar 

  17. Clasey JL, Weltman A, Patrie J, et al. Abdominal visceral fat and fasting insulin are important predictors of 24-hour GH release independent of age, gender, and other physiological factors. J Clin Endocrinol Metab 2001; 86: 3845–52

    Article  PubMed  CAS  Google Scholar 

  18. Conceicao FL, Bojensen A, Jorgensen JO, et al. Growth hormone therapy in adults. Front Neuroendocrinol 2001; 22: 213–46

    Article  PubMed  CAS  Google Scholar 

  19. Evans WJ. What is sarcopenia? J Gerontol A Biol Sci Med Sci 1995; 50: 5–8

    Article  PubMed  Google Scholar 

  20. Martin F. Frailty and the somatopause. Growth Horm IGF Res 1999; 9: 3–10

    PubMed  CAS  Google Scholar 

  21. United Nations, Procurement Division. World population prospects: the 2000 revision. Vol. III. New York (NY): United Nations, 2002: 189–95

    Google Scholar 

  22. Marcus R, Butterfield G, Holloway L, et al. Effects of short term administration of recombinant human growth hormone to elderly people. J Clin Endocrinol Metab 1990; 70: 519–27

    Article  PubMed  CAS  Google Scholar 

  23. Thompson JL, Butterfield GE, Marcus R, et al. The effects of recombinant human insulin-like growth factor-I and growth hormone on body composition in elderly women. J Clin Endocrinol Metab 1995; 80: 1845–52

    Article  PubMed  CAS  Google Scholar 

  24. Lange KH, Isaksson F, Rasmussen MH, et al. GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake. Clin Endocrinol 2001; 55: 77–86

    Article  CAS  Google Scholar 

  25. Cohn L, Feller AG, Draper MW, et al. Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-1 concentrations. Clin Endocrinol 1993; 39: 417–25

    Article  CAS  Google Scholar 

  26. Holloway L, Butterfield G, Hintz RL, et al. Effects of recombinant human growth hormone on metabolic indices, body composition, and bone turnover in healthy elderly women. J Clin Endocrinol Metab 1994; 79: 470–9

    Article  PubMed  CAS  Google Scholar 

  27. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124: 708–16

    PubMed  CAS  Google Scholar 

  28. Lange KH, Isaksson F, Juul A, et al. Growth hormone enhances effects of endurance training on oxidative muscle metabolism in elderly women. Am J Physiol Endocrinol Metab 2000; 279: E989–96

    PubMed  CAS  Google Scholar 

  29. Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. JAMA 2002; 288: 2282–92

    Article  PubMed  CAS  Google Scholar 

  30. Leung KC, Doyle N, Ballesteros M, et al. Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A 2003; 100: 1016–21

    Article  PubMed  CAS  Google Scholar 

  31. Weissberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone secretion, insulin-like growth factor I and GH binding protein in post-menopausal women. J Clin Endocrinol Metab 1991; 72: 374-81

    Google Scholar 

  32. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124: 708–16

    PubMed  CAS  Google Scholar 

  33. Rudman D, Feller AG, Cohn L, et al. Effects of human growth hormone on body composition in elderly men. Horm Res 1991; 36Suppl. 1: 73–81

    Article  PubMed  Google Scholar 

  34. Ho KY, Weissberger AJ. The antinatriuretic action of biosynthetic human growth hormone in man involves activation of the renin-angiotensin system. Metabolism 1990; 39: 133–7

    Article  PubMed  CAS  Google Scholar 

  35. Welle S, Thornton C, Statt M, et al. Growth hormone increases muscle mass and strength but does not rejuvenate myofibrillar protein synthesis in healthy subjects over 60 years old. J Clin Endocrinol Metab 1996; 81: 3239–43

    Article  PubMed  CAS  Google Scholar 

  36. Caidahl K, Eden S, Bengtsson B. Cardiovascular and renal effects of growth hormone. Clin Endocrinol 1994; 40: 393–400

    Article  CAS  Google Scholar 

  37. Taaffe DR, Jin IH, Vu TH, et al. Lack of effect of recombinant human growth hormone (GH) on muscle morphology and GH-insulin-like growth factor expression in resistance-trained elderly men. J Clin Endocrinol Metab 1996; 81: 421–5

    Article  PubMed  CAS  Google Scholar 

  38. Hennessey JV, Chromiak JA, DellaVentura S, et al. Growth hormone administration and exercise effects on muscle fiber type and diameter in moderately frail older people. J Am Geriatr Soc 2001; 49: 852–8

    Article  PubMed  CAS  Google Scholar 

  39. Johannsson G, Rosen T, Bosaeus I, et al. Long term growth hormone treatment increases bone mineral content and density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 1996; 81: 2865–73

    Article  PubMed  CAS  Google Scholar 

  40. Sugimoto T, Nakaoka D, Nasu M, et al. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol 1999; 51: 715–24

    Article  CAS  Google Scholar 

  41. Holmes SJ, Whitehouse RW, Swindell R, et al. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone deficiency. Clin Endocrinol 1995; 42: 627–33

    Article  CAS  Google Scholar 

  42. Rosen CJ, Bilezikian JP. Clinical review 123: anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86: 957–64

    Article  PubMed  CAS  Google Scholar 

  43. Weissberger AJ, Anastasiadis AD, Sturgess I, et al. Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clin Endocrinol (Oxf) 2003; 58: 99–107

    Article  CAS  Google Scholar 

  44. Yarasheski KE, Campbell JA, Kohrt WM. Effect of resistance exercise and growth hormone on bone density in older men. Clin Endocrinol 1997; 47: 223–9

    Article  CAS  Google Scholar 

  45. Munzer T, Harman SM, Hees P, et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J Clin Endocrinol Metab 2001; 86: 3604–10

    Article  PubMed  CAS  Google Scholar 

  46. Drake WM, Howell SJ, Monson JP, et al. Optimizing GH therapy in adults and children. Endocr Rev 2001; 22: 425–50

    Article  PubMed  CAS  Google Scholar 

  47. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10: 297–305

    Article  PubMed  CAS  Google Scholar 

  48. Chan J, Stampfer M, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6

    Article  PubMed  CAS  Google Scholar 

  49. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620–5

    Article  PubMed  CAS  Google Scholar 

  50. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. J Clin Endocrinol Metab 1998; 83: 379–81

    Article  Google Scholar 

  51. Toogood AA, O’Neill PA, Shalet SM. Beyond the somatopause: growth hormone deficiency in adults over the age of 60 years. J Clin Endocrinol Metab 1996; 81: 460–5

    Article  PubMed  CAS  Google Scholar 

  52. Toogood AA, Nass RM, Pezzoli SS, et al. Preservation of growth hormone pulsatility despite pituitary pathology, surgery and irradiation. J Clin Endocrinol Metab 1997; 82: 2215–21

    Article  PubMed  CAS  Google Scholar 

  53. Reutens AT, Hoffman DM, Leung K-C, et al. Evaluation and application of a highly sensitive assay for serum growth hormone in the study of adult GH deficiency. J Clin Endocrinol Metab 1995; 80: 480–5

    Article  PubMed  CAS  Google Scholar 

  54. Toogood AA, Adams JE, O’Neill PA, et al. Body composition in growth hormone deficient adults over the age of 60 years. Clin Endocrinol 1996; 45: 399–405

    Article  CAS  Google Scholar 

  55. Toogood AA, Adams JE, O’Neill PA, et al. Elderly patients with adult onset growth hormone deficiency are not osteopenic. J Clin Endocrinol Metab 1997; 82: 1462–6

    Article  PubMed  CAS  Google Scholar 

  56. Rosen T, Bengtsson B. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990; 336: 285–8

    Article  PubMed  CAS  Google Scholar 

  57. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism: West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357: 425–31

    Article  PubMed  CAS  Google Scholar 

  58. Bulow B, Hagmar L, Mikoczy Z, et al. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol 1997; 46: 75–81

    Article  CAS  Google Scholar 

  59. Beshyah SA, Johnston DG. Cardiovascular disease and risk factors in adults with hypopituitarism. Clin Endocrinol 1999; 50: 1–15

    Article  CAS  Google Scholar 

  60. Pfeifer M, Verhovec R, Zizek B. Growth hormone (GH) and atherosclerosis: changes in morphology and function of major arteries during GH treatment. Growth Horm IGF Res 1999; 9Suppl. A: 25–30

    Article  PubMed  Google Scholar 

  61. Jorgensen EV, Schwartz ID, Hvizdala E, et al. Neurotransmitter control of growth hormone secretion in children after cranial radiation therapy. J Pediatr Endocrinol 1993; 6: 131–42

    PubMed  CAS  Google Scholar 

  62. Klatz R. Grow young with HGH. 1st ed. New York (NY): HarperPerennial, 1998

    Google Scholar 

  63. Bartke A. Growth hormone and aging. Endocrine 1998; 8: 103–8

    Article  PubMed  CAS  Google Scholar 

  64. Bartke A. Delayed aging in Ames dwarf mice: relationships to endocrine function and body size. Results Probl Cell Differ 2000; 29: 181–202

    Article  PubMed  CAS  Google Scholar 

  65. Coschigano KT, Clemmons D, Bellush LL, et al. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000; 141: 2608–13

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The author has received research support from Novo Nordisk and Pfizer but this support was not directly related to the research discussed in this review.

Author information

Authors and Affiliations

  1. Division of Medical Sciences, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK

    Andrew A. Toogood

Authors
  1. Andrew A. Toogood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew A. Toogood.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Toogood, A.A. The Somatopause. Mol Diag Ther 3, 201–209 (2004). https://doi.org/10.2165/00024677-200403040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00024677-200403040-00001

Keywords

Search

Navigation